Drugs / Interleukin-10
Interleukin-10
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00001761 | Feb 1998 → Apr 2000 | granulomatosis with polyangiitis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT00040131 | Jan → Dec 2002 | bile duct disorder, gallbladder disorder, pancreatitis | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00001797 | Jan 1999 → Sep 2000 | psoriasis | National Cancer Institute (NCI) | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-07-12 | BioNet-Asia Co., Ltd. | Results Scientists discover how to improve vaccine response to potentially deadly bacterium bionet-asia.com ↗
They have shown in an animal model that targeting a key suppressive immune molecule (IL-10) during the delivery of a vaccine improves the ability of the vaccine to protect against infection. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-07-12 | BioNet-Asia Co., Ltd. | Scientists discover how to improve vaccine response to potentially deadly bacterium bionet-asia.com ↗ |
| 2023-08-25 | Elixiron Immunotherapeutics Inc. | Elixiron partners with Yang-Ming University to jointly develop new immunotherapy technology for head and neck cancer - novel drug combining tumor macrophage-targeting antibody with interleukin-10 fusion protein elixiron.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | interleukin-10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001797 ↗ |
| Known as | IL-10 | “Several studies have documented an essential role for interleukin-10 (IL-10) in preventing prolonged and exaggerated immune responses to antigens and irritants.” NCT00001797 ↗2“The purpose of this study is to assess the safety, tolerance, and immunologic effects of interleukin-10 (IL-10), in patients with Wegener's granulomatosis.” NCT00001761 ↗ |
| Known as | rhIL-10 | “Patients initially receiving active medication who wish to continue rhIL-10 therapy will be kept on the drug.” NCT00001797 ↗ |
| Known as | SCH 52000 | “Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis” NCT00001761 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Interleukin-10” NCT00001761 ↗ |
| Route | Subcutaneous | “IL-10 will be administered by subcutaneous injection” NCT00001761 ↗ |